Healthcare / Diagnostics & ResearchLSE
$8.29
+0.04 (+0.46%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 21%
FCF escenarios
weak_data · normalized FCF $7.9M · quality 47.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
23/100
D
Piotroski
0/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$57M
P/E
N/A
•EV/EBITDA
4744.0x
↑ROE
-15.7%
↓Gross Margin
N/A
•Debt/Equity
0.39
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-1.2%
FCF CAGR
—
FCF margin
-33.9%
FCF / Net income
2.64x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $46.8M · net income $-6.0M · FCF $-15.8M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $46.8M | $46.8M | $62.7M | $56.0M | $48.5M |
| Net Income | $-6.0M | $-6.0M | $10.7M | $16.1M | $-776000.00 |
| EBITDA | $1.2M | $1.2M | $17.8M | $14.0M | $2.7M |
| EPS | -0.01 | -0.01 | 0.02 | 0.02 | -0.00 |
| Operating Margin | -6.9% | -6.9% | 20.5% | 18.4% | 12.7% |
| Net Margin | -12.8% | -12.8% | 17.0% | 28.8% | -1.6% |
| Balance Sheet | |||||
| Debt/Equity | 0.39 | 0.39 | 0.29 | 0.37 | 0.08 |
| Current Ratio | 1.63 | 1.63 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-15.8M | $-15.8M | $7.9M | $12.1M | $14.6M |
| Returns | |||||
| ROE | -15.7% | -15.7% | 23.8% | 46.9% | -3.8% |
| Valuation | |||||
| P/E | — | — | 1232.26 | 1117.02 | — |
| EV/EBITDA | 4743.97 | 4743.97 | 736.64 | 1282.57 | 3308.51 |
| P/B | 148.92 | 148.92 | 294.25 | 524.49 | 442.83 |
| Growth & Yield | |||||
| Revenue Growth | -25.4% | -25.4% | 11.9% | 15.6% | — |
| EPS Growth | -156.1% | -156.1% | -34.0% | 2058.3% | — |
| Dividend Yield | 2.7% | 2.7% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-17.6%
Start / end P/E
n/dx → n/dx
EPS bridge
0.02 → -0.01
Residual
-20.3%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.